June 27, 2017 / 4:01 AM / a month ago

BRIEF-Natco Pharma gets final ANDA approval for azacitidine for injection

1 Min Read

June 27 (Reuters) - Natco Pharma Ltd:

* Says Natco receives final approval for generic azacitidine for injection for USA market

* Natco and marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the USA market in near future

* Vidaza is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS) Source text: (bit.ly/2tgILS3) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below